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Abstract  24 
Scope: This study examined to what extent plasma linoleic acid (LA) is modified by adiposity, 25 
and explored any association between plasma LA, demographics, dietary intakes, markers of 26 
metabolic health and haplotypes of the fatty acid desaturase (FADS) 1/2 genes. 27 
Methods and results: 820 participants with fasting blood samples from Irish National Adult 28 
Nutrition Survey were studied. Plasma fatty acids were determined using GC-MS. 15 SNPs of 29 
FADS 1/2 genes were genotyped. Plasma LA decreased while γ-linoleic acid and dihomo-γ-30 
linoleic acid increased in overweight/obese participants (P≤0.002). Participants in the highest 31 
quartile of plasma LA showed decreased plasma markers of de novo lipogenesis, insulin resistance 32 
and of inflammation (TNF-α, PAI-1) (P≤0.005). Adiposity (waist circumference and body fat) was 33 
strongly inversely associated with plasma LA accounting for 11.8% of variance observed, which 34 
was followed by FADS1/2 haplotypes (3.9 %), quantity and quality of carbohydrate intakes 35 
(3.8 %), dietary PUFA intakes (3.7 %), systolic blood pressure (3.6 %) and age (3.2 %). 36 
Conclusion: Plasma LA was inversely associated with adiposity, followed by haplotypes of 37 
FADS1/2 genes, carbohydrate intakes and dietary PUFA intakes. The association observed 38 
between plasma LA and adiposity may be linked to decreased de novo lipogenesis, insulin 39 
resistance and inflammation.  40 
  41 
Introduction 42 
The essential fatty acid, dietary linoleic acid (LA) has traditionally been considered as protective 43 
against cardiovascular disease (CVD) [1] and coronary heart disease (CHD) [2, 3]. Randomized 44 
controlled trials suggest that diets high in PUFA may result in lower fat accumulation relative to 45 
other fatty acids [4, 5]. A number of observational studies have also attempted to relate circulating 46 
or plasma LA to health outcomes. In healthy adults, two recent studies which completed pattern 47 
analysis of a suite of plasma and erythrocyte fatty acids identified patterns rich in LA, both of 48 
which were associated with healthier phenotypes [6, 7]. The Epic Interact Study reported a strong 49 
inverse association between plasma linoleic acid and type 2 diabetes incidence [8]. Other studies 50 
in older populations or  those at risk of CVD have suggested that circulating LA is inversely related 51 
to adiposity [9, 10], central adiposity [5, 11] and risk of the metabolic syndrome and type 2 diabetes, 52 
but not CHD  [12, 13]. In a middle-aged community cohort, half of whom were obese, erythrocyte 53 
LA was inversely related with insulin resistance measured by HOMA score and IL-6 [11]. 54 
However any relationship between plasma LA and health may be influenced by body weight status, 55 
with initial reports suggesting that circulating LA is positively related to circulating concentrations 56 
of soluble intercellular adhesion molecule-1 in (ICAM, a marker of endothelial activation and 57 
predictor of future CVD events) obese participants, the opposite being observed for normal weight 58 
adults [6]. Beyond this, little is known in terms of to what extent circulating LA level is associated 59 
with adiposity and how circulating LA is related to other markers of inflammation and metabolic 60 
health, particularly in younger, healthy cohorts.  61 
The enzymes Δ-5 and Δ-6 desaturase, encoded by fatty acid desaturase (FADS) 1 and 2 genes, are 62 
the rate limiting enzymes regulating synthesis of long-chain n-6 polyunsaturated fatty acids (PUFA) 63 
such as the conversion of LA to γ-linoleic acid (GLA, 18:3n-6), dihomo-γ-linoleic acid (DGLA, 64 
20:3n-6) and arachidonic acid (ARA, 20:4n-6). Using genotype and haplotype analysis, circulating 65 
LA levels were associated with  FADS 1 and 2 genes [14-16], with carriers of minor alleles 66 
demonstrating increased circulating LA [17]. Generally, the interaction between adiposity, dietary 67 
intakes, circulating LA and haplotypes of FADS1/2 genes and how any interaction may affect 68 
markers of inflammation and risk of metabolic syndrome (MetS) remain largely unknown. Against 69 
this backdrop, the objective of present study was to explore, in a cohort of healthy Irish adults, the 70 
association between plasma LA and adiposity, demographics, dietary intakes and haplotypes of 71 
FADS1/2 genes.  72 
 73 
Participants and methods 74 
Design and population 75 
This paper uses data from the cross-sectional national food survey of Irish adults: the National 76 
Adult Nutrition Survey (NANS) [18]. The NANS (May 2008-April 2010) examined the habitual 77 
food and beverage intake of a representative sample (n=1500, 740 males and 760 females) of Irish 78 
adults aged 18-90 years who were free-living and who were not pregnant or breast feeding. Ethical 79 
approval was obtained from University College Cork Clinical Research Ethics Committee of the 80 
Cork Teaching Hospitals and the Human Ethics Research Committee of University College Dublin 81 
(ECM 3 (p) 4 September 2008). All procedures in this study were in accordance with the guidelines 82 
laid down in the Declaration of Helsinki, with written informed consent obtained from all 83 
participants.  84 
As no national identification system exists in the Republic of Ireland, hence participants were 85 
randomly selected from the Data Ireland (National Postal Service) database of free-living adults 86 
in Ireland in 20 geographical clusters nationwide, with clusters selected to provide proportional 87 
representation across the urban-rural continuum and a minimum of 100 participants in the least 88 
populated age and sex subgroups. A sample of 1500 free-living adults, representing the Irish 89 
population of over 4 million people participated in the dietary survey with analyses of the profile 90 
of NANS showing it to be representative of adults in Ireland with respect to age, gender, social 91 
class and urban/rural location compared to the most recent Irish census [18-20]. The overall 92 
response rate was 60%. In the present paper, only participants for whom fatty acid profiles were 93 
available and valid reporters are included, leaving a final sample size of 820 (which remained 94 
representative of the entire cohort). Demographics of participants who provided fasting blood 95 
samples were reported elsewhere [20]. 96 
 97 
Dietary assessment 98 
Food and beverage consumption was assessed using a 4-day semi-weighed food record. Initial 99 
nutrient analysis was carried out using the Weighed Intake Software Program (Tinuviel Software, 100 
Anglesey UK), which uses data from McCance & Widdowson’s The Composition of Foods, fifth 101 
and sixth editions plus all nine supplemental volumes as described elsewhere [18] to generate 102 
nutrient intake data. Adjustments were made to the food composition database to take account of 103 
recipes, nutritional supplements, commonly consumed generic Irish food and new foods on the 104 
market. All entries were double-checked by the researcher and a random sample was checked by 105 
another researcher in-house to minimize the chance of error. 106 
 107 
 108 
Plasma fatty acids analysis 109 
The procedures used to determine plasma fatty acids profiles in the fasted samples are described 110 
elsewhere [6]. In brief, plasma lipids were extracted using the method of Bligh & Dyer [21]. 111 
Butylated hydroxytoluene (BHT) and heptadecanoic acid (2 mg/mL in methanol) were used as 112 
antioxidant and internal standard, respectively. Extracted plasma lipids were transesterified using 113 
boron tri-fluoride-methanol solution (14%), and the resulting fatty acid methyl esters (FAME) 114 
were extracted twice using hexane and water [22]. FAMEs were separated and identified by gas 115 
chromatography coupled with mass spectrometry (GC-MS) HP 5890 Series II, HP 5971A (Hewlett 116 
Packard) using an Omegawax 250 fused silica capilary column (30m×0.25mm×0.25μm film 117 
thickness, (Supelco). 38 known peaks were identified (including 17:0 as internal standard) using 118 
GC-MS. Laboratory CV of LA in fasting blood samples was 14.4%. The demographics of 119 
participants who provided a blood sample (76% of total sample), and those in the entire sample 120 
have been reported elsewhere, with no significant differences identified [19]. 121 
 122 
Assessment of biochemical profiles and metabolic risk factors 123 
Collection of anthropometric measurements (including weighed body weight, BMI, waist 124 
circumference, body fat and blood pressure) and biochemistry parameters assessment has been 125 
described elsewhere [23, 24]. In brief, anthropometric measurements were carried out in duplicate 126 
by trained researchers using standardized methods.  % body fat and weight were collected using 127 
Tanita ® Model BC-420 MA body composition analyzers (Tanita Ltd. GB) with a % CV of 0.73% 128 
and 0.02% respectively. Height was measured using a Leicester portable height measure (Seca, 129 
Birmingham, UK). All scales were calibrated and placed on a hard surface prior to use with 130 
participants asked to remove any heavy clothing, accessories or shoes as appropriate. Hip and waist 131 
circumference were measured using non-stretch measuring tape to the nearest 0.1cm with % CV 132 
of 0.17% and 0.13% respectively. Weight class was created as normal weight (BMI ˂ 25 kg/m2), 133 
overweight (BMI 25-30 kg/m2) and obese (BMI > 30 kg/m2). Blood samples were collected by 134 
venepuncture by trained phlebotomists and stored appropriately until they reached the lab within 135 
5 hours of collection for processing and further storage at -800C until further analysis.  Biochemical 136 
values were assessed using a clinical bioanalyzer (Randox Daytona, Randox Laboratories) and 137 
cytokines and hormones using a biochip array system (Evidence Investigator, Randox Laboratories) 138 
except adiponectin which was measured by ELISA (ALPCO Diagnostics Kit). All samples were 139 
run in duplicate with standard quality control procedures followed in both analyses to ensure data 140 
integrity.  Homeostatic model assessment-IR (HOMA-IR) score was calculated using the formula 141 
(fasting insulin µU/mL x fasting glucose mmol/L)/22.5 [25]. Quantitative sensitivity check index 142 
(QUICKI) score was calculated as follows: 1/(log(fasting insulin µU/mL) + log(fasting glucose 143 
mg/dL) [26]. Diagnosis of MetS was defined according to the National Cholesterol Education 144 
Programme’s Adult Treatment Panel III criteria for MetS 2001 [27] including fasting blood 145 
glucose concentrations of 5.5-7.0 mmol/L, serum triacylglycerol (TAG) concentrations of ≥1.7 146 
mmol/L, HDL<1.0 mmol/L (men), <1.3mmol/L (women), blood pressure ≥130/85mmHg and 147 
waist circumference >102cm (men) & >88cm (women).  Physical activity was estimated using a 148 
tri axial accelerometer (Actigraph GT1M, ActiGraph, LLC) for the four days of the survey period 149 
[28]. 150 
 151 
Genotyping 152 
15 single nucleotide polymorphisms (SNPs) were selected based on previous studies which have 153 
been shown to be associated with circulating LA [14, 16, 29] and human health [30].  SNP 154 
genotyping was then conducted by the LGC group (www.lgcgroup.com) using their proprietary 155 
KASPar polymerase chain reaction technique [31].  156 
 157 
Statistical analysis 158 
Plasma n-6 PUFA (18:2n-6, 18:3n-6, 20:2n-6, 20:3n-6, 20:4n-6, 22:4n-6) profiles were compared 159 
across normal weight, over-weight and obese participants. Quartiles of plasma LA, GLA and 160 
DGLA were obtained using SPSS version 20.0 (IBM Inc. Chicago, USA). General linear contrast 161 
model adjusted for age, body fat, blood pressure, waist circumference, waist hip ratio, smoking 162 
status, working energy expenditure, and BMI was applied across plasma LA quartiles for 163 
comparison of percentage of plasma fatty acid, nutrient density (calculated as % total energy (TE) 164 
or μg or mg/10MJ), and circulating concentrations of biochemical biomarkers. Differences in 165 
gender, social class, smoking habits, contraceptive use and metabolic risk factors across quartiles 166 
were compared using Chi-square test. Δ-5-desaturase (D5D) and Δ-6-desaturase (D6D) were 167 
estimated using fatty acid product/precursor ratios as following: D6D=C18:3n-6/C18:2n-6, and 168 
D5D=C20:4n-6/C20:3n-6 [32]. Contraceptive use in females was not controlled for in subsequent 169 
analysis due to the low proportion (3.5 %) of oral contraceptive users in NANS with no difference 170 
in proportions across LA quartiles (P=0.094). One-way ANOVA was also applied across fatty acid 171 
clusters for demographic variables including age, BMI, waist circumference, body fat physical 172 
activity, waist hip ratio, and blood pressure.  Skewed data were log transformed to obtain 173 
normalized distribution. Where appropriate in this exploratory analysis, Bonferroni correction was 174 
applied by adjusting the p-values by the number of traits in each table. p-values that exceed 1.0 175 
after correction for multiple testing have been marked down to 1.000. 176 
  177 
Linkage disequilibrium (LD) was assessed using Haploview 4.2 [33], and haplotype blocks were 178 
obtained using the Gabriel’s definition [34]. Haplotype frequency was estimated using Haplo.Stat 179 
1.7.6 package in R 3.2 (R Foundation for Statistical Computing, Vienna, Austria; ISBN 3–900051-180 
07–0; Internet: http://www.R-project.org). Multiple linear regression with stepwise backward 181 
selection was used to explore possible determinants of plasma LA status. Demographic and dietary 182 
intake variables were included in the initial model and haplotypes were included in the final model 183 
regardless of the significance. Partial R2 was used to calculate the explained variation of each 184 
determinants in the final model. The association between plasma LA and haplotypes were 185 
estimated using HapStat 3.0 [35].  186 
 187 
Results 188 
A complete fasting plasma fatty acid dataset of 820 participants (mean age 41.9 ± 16.7 years, with 189 
412 males and 408 females) were included in the analysis.  Initial examination showed that plasma 190 
LA and estimated Δ-5-desaturase activity decreased while GLA, DGLA, and Δ-6-desaturase 191 
activity increased across the body weight categories in Irish adults (P ≤ 0.003) (Table 1). 192 
Demographics and markers of metabolic health were compared across the quartiles of plasma LA 193 
(Table 2 and Table 3), GLA and DGLA (Table S1) to explore any association between plasma LA, 194 
GLA, DGLA and health parameters. As quartiles of plasma LA showed greater separation in terms 195 
of demographics and markers of metabolic health (as described below) therefore subsequent 196 
analysis focused on plasma LA only.   197 
 198 
Demographics and dietary intakes 199 
As shown in Table 2, participants in the highest quartile of plasma LA displayed a healthier 200 
phenotype.  Compared with participants in quartile 1 (Q1), participants in quartile 4 (Q4) were 201 
younger (50.7 years vs. 36.5 years, P<1.9 x 10-19), with lower adiposity (including BMI, body fat, 202 
waist circumference and waist hip ratio, P<3.1 x 10-6), blood pressure (131.9/81.4 mmHg vs. 203 
118.2/75.3 mmHg, P<2.2x10-7), metabolic risk and a lower proportion were overweight (45.3 % 204 
vs. 32.1 %) or obese (34.7 % vs. 14.0 %) (P ≤ 2.7×10-7). Higher work activity energy expenditure 205 
was observed for Q4 (47.8 MET hrs/wk vs. 66.1 MET hrs/wk, P<0.026) and a greater proportion 206 
of participants that never smoked (41.9 % vs. 62.7 %, P<0.001). Dietary intakes across the quartiles 207 
of plasma LA are shown in Table S2.  Across plasma LA quartiles, intake of starch, PUFA, n-6 208 
PUFA and dietary fibre significantly increased (P < 0.003).  209 
 210 
Markers of metabolic health and plasma fatty acids 211 
The clinical chemistry biomarkers and plasma fatty acid levels across quartiles are shown in Table 212 
3.  After adjustment for confounders, insulin, C-peptide, TAG, HOMA-IR, PAI-1, TNF-α, hs-CRP 213 
decreased, while QUICKI and adiponectin increased across plasma LA quartiles (P≤0.005). 214 
Regarding plasma fatty acids related to the n-6 PUFA pathway, 20:2n-6, 18:3n-6, 20:3n-6 and 215 
D6D decreased across plasma LA quartiles (P ≤ 0.019), whereas total n-6 PUFA and n-6/n-3 ratio 216 
increased (P≤1.4 x 10-138).  Plasma total SFA and total MUFA decreased (P ≤ 1.1 x 10-21), as did 217 
plasma fatty acids related to de novo lipogenesis (DNL, including 14:0, 14:1n-5, 16:0, 16:1n-7 and 218 
18:1n-9) were also significantly decreased (P≤4.7×10-6) across plasma LA quartiles.  219 
 220 
 221 
Effects of haplotypes on plasma n-6 PUFA profiles 222 
The degree of LD between the analyzed genetic polymorphisms are shown in Figure S1. 223 
Haplotypes were statistically reconstructed for three windows (Table 4). The first window 224 
contained all 15 SNPs from rs174537 to rs482548. Seven haplotypes were identified in this 225 
window with a frequency over 1 %, of which haplo 7 was the most common (53.9 %) haplotype 226 
with no minor allele. Compared with haplo 7, haplo 1, 3, 4, 5 were positively associated with 227 
plasma LA (P ≤ 0.02), with all of the haplotypes except haplo 2 negatively associated with D5D 228 
and D6D (P ≤ 6.44×10-3) (Table 5). The second window contained 8 SNPs from rs174537 to 229 
rs99780, and four haplotypes were reconstructed with frequency above 1 %. Compared with the 230 
most common haplotype (haplo 4 with frequency of 65.6 %) in the second window, all the other 231 
haplotypes were positively associated with plasma LA while negatively associated with D5D and 232 
D6D (P ≤ 1.67×10-3). The third window contained 3 SNPs from rs2524299 to rs174583, and three 233 
haplotypes were reconstructed with a frequency above 1 %. Compared with the most common 234 
haplotype (haplo 3 with frequency of 65.5 %) in the third window, all of the other haplotypes were 235 
positively associated with plasma LA while negatively associated with D5D and D6D (P ≤ 236 
1.64×10-3). Haplotypes in the second and third windows explained the variance of plasma LA by 237 
3.5 %, respectively (Table S2 and Table S4). We also explored the interaction of dietary PUFA 238 
intakes and haplotypes but no significant interaction was found after adjustment for confounders 239 
(P ≥ 0.057). 240 
 241 
Possible determinants of plasma LA 242 
Multiple linear regression of possible determinants of plasma LA are shown in Table 6. Of the 243 
variables tested, adiposity measures (waist circumference and body fat) were most strongly 244 
inversely associated with plasma LA accounting for 11.8 % of the total variance, followed by 15-245 
SNP haplotypes (3.9 %), quantity and quality of carbohydrate intakes (3.8 %), dietary PUFA 246 
intakes (3.7 %), systolic blood pressure (3.6 %) and age (3.2 %). 247 
 248 
Discussion 249 
In this study, higher plasma LA was related to a healthier phenotype and metabolic profile in Irish 250 
adults. We observed an inverse relationship between plasma LA and the adiposity measures 251 
studied, with waist circumference and body fat most strongly associated with plasma LA, followed 252 
by dietary PUFA and haplotypes of FADS genes. The beneficial effects of plasma LA may be 253 
associated with decreased biomarkers of DNL, insulin resistance and inflammation, all of which 254 
have previously been linked with the pathogenesis of obesity [36, 37].  255 
A growing body of evidence suggests that LA may influence health outcomes. An inverse 256 
relationship between serum LA and all-cause mortality (but not CVD risk) has been described in 257 
a cohort of healthy older adults [38]. Further observational studies report lower plasma 258 
phospholipid LA and higher GLA and DGLA levels in overweight/obese adolescents [9, 39] and 259 
higher proportions of serum and cholesterol ester LA being associated with lower markers of 260 
abdominal obesity and BMI and reduced T2D incidence [8, 40-42].  Altered desaturase activity is 261 
documented in overweight and obese participants and those with T2D, with reports of elevated 262 
D6D and decreased D5D [8, 9, 39, 41].  Growing evidence suggests that such benefits may arise 263 
from effects of LA on body fat accumulation. Animal trials and human RCTs indicate that 264 
compared to SFA, high LA intakes result in improvements in body composition outcomes [4, 5, 265 
43]. There is some evidence of similar benefits in populations with regular dietary LA intakes 266 
whereby serum or erythrocyte LA was inversely related to body fat, specifically trunk fat in a 267 
healthy elderly cohort [5] and in a middle aged relatively healthy cohort [11]. Of interest, such 268 
benefits were not observed for erythrocyte n-3 PUFA or for the MUFA, OA [11]. In the present 269 
study, we confirm these fatty acid profiles of elevated LA and altered patterns of D5D and D6D 270 
activity according to body weight status and without significant alterations in n-3 PUFA status, in 271 
this nationally representative cohort of healthy adults aged 18-90 y. Our study adds to evidence 272 
which is suggestive of either a protective effect of circulating LA on obesity and/or, of altered fatty 273 
acid metabolism in the presence of excess body weight. However, desaturase activities based on 274 
ratio of circulating fatty acids are indirect measure of enzyme activities which may also be affected 275 
by lifestyle. Further, our results are presented as percentage, rather than absolute, values which 276 
may imply co-dependence on all other fatty acids. Further research is required to explore the 277 
specific health implications of plasma LA as well as any interactions between dietary PUFA 278 
intakes and circulating fatty acid profiles.  279 
Previous studies have demonstrated a similar inverse association between circulating LA and 280 
biomarkers such as insulin, glucose, TAG, hs-CRP, with higher adiponectin concentrations and 281 
with reduced risk of insulin resistance, metabolic syndrome, cardio-metabolic risk score and T2D 282 
[5, 8-10, 44-46].  In addition, our results show decreased inflammation markers such as PAI-1 and 283 
TNF-α across plasma LA quartiles, elevated levels of which have been linked to obesity [47]. 284 
Nevertheless, this decrease in markers of metabolic health in the present study remained significant 285 
even when controlling for BMI and waist circumference.  A negative association between plasma 286 
LA and inflammation markers e.g. IL-6 and CRP has been reported elsewhere [11, 48].  Such 287 
associations may be explained by a recent study, showing that LA may suppress the expression of 288 
toll-like receptor 4 (TLR4), phosphorylation levels of c-Jun amino-terminal kinases (JNK) and 289 
agouti-related protein (AgRP) [49]. AgRP promotes food intake[50], and an absence of JNK1 may 290 
lead to decreased adiposity and improved insulin sensitivity [51]. Such potential mechanisms may 291 
help explain the decreased adiposity and markers of inflammation observed in participants in the 292 
highest quartile of plasma LA (Q4). Moreover, bioactive metabolites of LA such as nitro-linoleic 293 
acid may be anti-inflammatory by reducing the activation and gene transcription of nuclear factor-294 
κB while stimulating activation of peroxisome proliferator–activated receptor γ [52].  Further 295 
research is required in this area. 296 
It is possible that the decreased plasma LA observed in overweight/obese participants in our study 297 
may be linked to DNL. DNL is a, typically inhibited, pathway of converting excess carbohydrate 298 
to esterified fatty acids which are subsequently stored as TAG in the liver and adipose tissue [53]. 299 
Increased DNL has been observed in the obese [36, 54], in non-alcoholic fatty liver disease [55] 300 
and under conditions of insulin resistance, including inflammation [53].  Further, DNL stimulated 301 
hepatic TAG are reported to be enriched with palmitic acid while depleted in LA [56]. In our study, 302 
in addition to decreased levels of plasma LA observed in obese participants, all adults in the lowest 303 
quartile of plasma LA had a fatty acid profile suggestive of DNL (i.e. reduced LA, increased 14:0, 304 
16:0, 16:1n-7) and with patterns of biochemical markers suggestive of insulin resistance and low-305 
grade inflammation.  Dietary intakes may also influence DNL, whereby high carbohydrate, low 306 
fat diets may promote DNL, particularly when dietary sugar is substituted for starch [57]. In 307 
contrast high dietary fibre intakes can yield less short-chain fatty acids, which may suppress DNL 308 
and improve insulin sensitivity [58, 59]. In our study, participants had a relatively high fat diet 309 
(mean daily intake of 33.8 %TE) and moderate carbohydrate intakes (mean daily intake of 310 
42.6 %TE). Nevertheless, participants with the lowest circulating plasma concentrations (quartile 311 
1) had lower intakes of starch and dietary fibre, while regression analysis identified quantity and 312 
quality of carbohydrate intake as the third largest determinant of plasma LA (3.8%). Collectively, 313 
in this cohort of generally healthy adults there exists a group with lipid and metabolic profiles 314 
suggestive of possible future risk and who can be easily identified by nature of circulating plasma 315 
LA concentrations. This is supportive of the hypothesis which aims to clarify whether endogenous 316 
metabolites or lipids constitute simple and effective biomarkers of metabolic diseases such as 317 
NAFLD, type 2 diabetes and metabolic syndrome [6, 55]. 318 
Polymorphism and haplotype of FADS1/2 genes have been reported to be linked to long-chain 319 
PUFA concentrations/metabolism such as for LA, ARA, D5D and D6D [14, 30, 60, 61]. To our 320 
knowledge, only one study reported variation of haplotypes of FADS genes in relation to serum 321 
phospholipid , which was higher compared with the present study (9.2 % vs. 3.9 %) [14]. This may 322 
due to different SNPs, lipid fractions and study population included. Potential dietary PUFA 323 
intakes × haplotypes interactions were also explored in the present study, however, the P values 324 
were above the significant threshold (P ≥ 0.057) after adjustment for confounders [62]. The impact 325 
of dietary intakes × haplotypes/genotype interactions on circulating n-6 PUFA profiles have been 326 
poorly explored and merits future study [63]. Haplotype analysis of FADS genes also revealed 327 
significant association between haplotypes and concentration of hs-CRP and TAG [15, 16]. 328 
Similarly, results of genome-wide association studies reported that carriers of the minor allele of 329 
rs174537 and rs174547 showed lower total cholesterol HDL-C and LDL-C [64, 65]. However, no 330 
significant association was identified in our study between haplotypes and inflammation markers, 331 
suggesting that haplotype may not be involved in the association between plasma LA and 332 
inflammation.  333 
The major strength of the present study is that we included a comprehensive group of inflammation 334 
markers, genotype information as well as the combination of dietary and plasma fatty acid data 335 
which clearly showed the beneficial effects of a higher plasma LA. Limitations of the study include 336 
the observational study design that is unable to reveal the causality of the relations.  In this national 337 
food consumption survey (NANS), body composition measurements were collected by trained 338 
field workers with body fat assessed using a Tanita® body fat analyser rather than gold standard 339 
methods such as magnetic resonance imaging, computed tomography or DEXA scans. This was 340 
due to the practical simplicity of using Tanita® as part of a national food consumption survey. It 341 
has been reported that Tanita® is not associated with a clinically significant decrement in 342 
performance relative to traditional impedence devices [66] although it is recognized that this 343 
technique may slightly overestimate fat mass relative to DEXA [67] and MRI [68]. A further 344 
limitation of this study was the use of total plasma fatty acids rather than lipid fractions given that 345 
different associations have been reported between phospholipid and cholesterol esters [69]. Finally, 346 
we acknowledge that alterations in proportions of circulating fatty acids with age are well 347 
described, with reductions in erythrocyte concentrations of linoleic acid reported to be in the order 348 
of 2 percentage points per decade [70]. In our study, those in the lowest quartile of plasma LA 349 
were older than those in the highest quartile. Hence, it is possible that age-related influences on 350 
body fat accumulation and on metabolic health may have influenced outcome. However, we 351 
controlled for age in all relevant analysis to attempt mitigate any such risk.  352 
In conclusion, our results showed that plasma LA was inversely associated with adiposity, 353 
followed by haplotype of FADS genes and dietary intakes. A higher plasma LA profile was related 354 
to a healthier phenotype and markers of metabolic health even when controlling for BMI and waist 355 
circumference. Future work is needed to better understand the mechanism of obesity modified 356 
plasma LA profile on human health.  357 
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Table 1 Profile of plasma n-6 fatty acids between normal weight, overweight and obese Irish adults (n=781) 
 Normal weight  
(n=294, % males=40.5) 
Overweight  
(n=301, % males=58.8) 
Obese  
(n=186, % males=52.2) 
P-trend 
 Mean SD Mean SD Mean SD  
18:2n-6 27.30 3.39 25.65 3.52 24.69 3.85 2.9×10-7 
18:3n-6 0.52 0.18 0.58 0.18 0.59 0.20 0.003 
20:2n-6 0.37 0.19 0.38 0.16 0.39 0.22 1.000 
20:3n-6 2.02 0.47 2.02 0.47 2.11 0.47 0.003 
20:4n-6 7.80 1.99 7.73 1.75 7.41 1.74 0.312 
22:4n-6 0.24 0.09 0.23 0.08 0.25 0.09 1.000 
D5D 4.08 1.53 4.10 1.95 3.71 1.32 8.6×10-4 
D6D 0.020 0.01 0.024 0.01 0.025 0.01 1.6×10-5 
Participants who are under-weight (n=5) and participants with missing BMI value were excluded from this analysis (n=34). D5D: 
delta-5-desaturase (20:4n6/20:3n6); D6D: delta-6-desaturase (18:3n6/18:2n6). 
General linear contrast model adjusted for age and gender was used, P-values were corrected by multiple number of traits. 	P-
values that exceed 1.0 after correction for multiple testing have been marked down to 1.000. 
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Table 2. Demographics across quartiles of plasma linoleic acid in Irish adults (n=820). 
  Quartiles of plasma linoleic acid  
 1 (n=205) 2 (n=205) 3 (n=205) 4 (n=205) P-trend 
 % LA=21.1 % LA=25.0 % LA=27.4 % LA=30.5 
  Mean SD Mean SD Mean SD Mean SD 
Age (years) 50.67 17.00 42.31 16.89 38.04 15.06 36.46 14.02 1.9×10-19 
BMI (kg/m2) 29.02 5.75 27.07 4.99 26.66 4.60 25.30 3.73 2.2×10-12 
Body fat (%) 31.46 10.12 28.66 9.16 28.68 8.66 26.32 8.74 3.1×10-6 
Waist circumference (cm) 97.83 15.27 91.05 13.76 90.00 12.95 85.56 11.54 1.2×10-15 
Waist hip ratio 0.92 0.09 0.87 0.09 0.86 0.08 0.85 0.07 3.5×10-13 
Systolic blood pressure (mmHg) 131.93 18.12 123.86 16.03 122.22 17.38 118.23 15.12 1.7×10-13 
Diastolic blood pressure (mmHg) 81.44 11.13 78.05 10.43 76.86 10.69 75.34 9.97 2.2×10-7 
Physical activity (MET hrs/wk)          
  Work activities  47.77 60.31 58.88 52.81 62.70 58.90 66.08 70.89 0.026 
  Recreational activities  27.55 41.01 37.64 51.90 38.37 56.67 34.12 39.37 1.000 
Gender M=118,F=87 M=105,F=100 M=93,F=112 M=96,F=109 0.061 
Oral contraceptive users (%) 2.9 2.4 6.3 2.4 0.094 
Metabolic risk factor (%)     3.7×10-20 
  No Risk Factors 18.0 39.0 46.3 60.5  
  1-2 Risk Factors 53.2 48.3 47.3 27.8  
  > 3 Risk Factors 22.0 8.8 4.9 4.9  
Smoking status (%)     0.001 
  Current smoker  22.2 18.6 21.5 18.6  
  Former smoker 36.0 27.9 21.5 18.6  
  Never smoke 41.9 53.4 57.1 62.7  
Social class (%)     0.153 
  Professional/managerial/technical  48.2 46.2 42.8 43.2  
  Non-manual skilled  12.8 17.6 19.9 18.1  
  Manual skilled 21.0 13.6 11.9 14.1  
  Semi-skilled/unskilled  17.9 22.6 25.4 24.6  
Weight class     2.7×10-7 
  Normal weight 20.0 37.8 38.6 53.9  
  Overweight 45.3 37.8 39.1 32.1  
  Obese 34.7 24.5 22.3 14.0  
Comparisons of age, BMI, body fat, waist circumference, physical activity and blood pressure across quartiles were assessed using 
Linear contrast analysis; comparisons of gender, smoking status, social class, weight class and metabolic risk factor were based on 
chi square statistic.P-values were corrected by multiple number of traits. 	P-values that exceed 1.0 after correction for multiple 
testing have been marked down to 1.000. M: males; F: females. 
Table 3. Concentration of biochemistry biomarkers across quartiles of plasma linoleic acid in Irish adults (n=820). 
 Quartiles of plasma linoleic acid 
 1 (n=205) 2 (n=205) 3 (n=205) 4 (n=205) P-trend 
 % LA=21.1 % LA=25.0 % LA=27.4 % LA=30.5 
  Mean SD Mean SD Mean SD Mean SD 
Metabolism          
  Glucose (mmol/l) 5.71 1.21 5.23 1.28 5.11 0.66 5.03 0.86 0.058 
  Insulin (µIU/ml) 12.77 10.80 8.73 6.15 8.97 8.08 7.48 5.28 5.7×10-5 
  C-Peptide (ng/ml) 3.00 2.51 2.08 2.41 1.93 1.97 1.48 1.40 7.0×10-5 
  Triglyceride (mmol/l) 1.83 0.88 1.28 0.58 1.03 0.38 0.86 0.33 2.1×10-35 
  Total Cholesterol  (mmol/l) 5.02 1.10 5.02 0.93 4.96 1.01 4.75 0.94 1.000 
  LDL Cholesterol  (mmol/l) 2.72 0.93 2.90 0.79 2.89 0.92 2.76 0.80 0.160 
  HDL Cholesterol  (mmol/l) 1.47 0.41 1.54 0.41 1.60 0.43 1.59 0.42 1.000 
  HOMA-IR 3.43 3.76 2.09 1.74 2.16 2.59 1.71 1.33 9.1×10-6 
  QUICKI 0.34 0.04 0.36 0.04 0.36 0.04 0.37 0.04 1.9×10-5 
Immune function and metabolic health 
  PAI-1 (ng/ml) 25.46 9.16 24.00 9.68 22.11 8.60 20.29 7.08 1.2×10-4 
  TNF-α (pg/ml) 7.60 2.70 6.99 2.60 6.66 2.48 6.28 1.55 0.005 
  High Sensitivity CRP (mg/l) 3.49 3.27 2.84 3.00 2.35 2.40 2.08 2.09 0.003 
  Adiponectin (μg/ml) 5.16 2.69 5.78 3.28 6.52 3.28 6.35 3.13 0.002 
  Leptin Soluble Receptor (ng/ml) 27.16 6.76 27.19 7.24 27.48 7.21 27.49 6.27 1.000 
  Resistin(ng/ml) 5.92 2.50 6.30 2.88 6.01 2.64 6.04 2.72 1.000 
Plasma fatty acids (%) and desaturase 
Total n-6 PUFA 32.1 2.99 36.1 2.02 38.38 1.93 41.04 2.32 1.4×10-138 
  18:2n-6  21.07 2.03 25.02 0.78 27.36 6.17 30.50 1.86 4.0×10-252 
  20:2n-6  0.44 0.25 0.37 0.15 0.35 0.17 0.35 0.13 1.9×10-7 
  18:3n-6  0.62 0.20 0.58 0.17 0.54 0.18 0.51 0.17 8.8×10-5 
  20:3n-6 2.05 0.49 2.13 0.49 2.02 0.46 1.97 0.42 0.019 
  20:4n-6  7.62 2.18 7.71 1.72 7.89 1.79 7.49 1.64 1.000 
  22:4n-6 0.25 0.09 0.24 0.08 0.23 0.09 0.23 0.08 0.156 
  EPA 1.56 1.00 1.43 0.78 1.32 0.80 1.18 0.70 1.000 
  DHA 2.42 0.97 2.47 0.93 2.44 0.93 2.25 0.85 1.000 
  D5D 3.95 1.68 3.82 1.30 4.18 2.09 4.01 1.40 1.000 
  D6D 0.03 0.01 0.02 0.01 0.02 0.01 0.02 0.01 4.7×10-35 
n-6/n-3 ratio 5.96 1.64 6.72 1.67 7.59 2.50 8.43 2.26 1.2×10-17 
  Total SFA 37.16 3.50 35.77 3.07 34.65 2.77 33.63 2.81 6.0×10-32 
  Total MUFA 24.94 3.63 22.41 3.60 21.42 3.14 20.07 3.13 1.1×10-21 
  14:0 1.47 0.44 1.19 0.31 1.01 0.32 0.93 0.26 7.8×10-30 
  16:0 24.48 1.96 23.20 1.45 22.50 1.35 21.56 1.18 9.1×10-53 
  18:0 9.86 2.61 9.97 2.62 9.82 2.59 9.80 2.49 0.288 
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  14:1n-5 0.14 0.07 0.10 0.05 0.08 0.05 0.06 0.04 4.0×10-30 
  16:1n-7 3.43 0.94 2.71 0.61 2.30 0.48 1.88 0.49 7.5×10-71 
  18:1n-9 20.38 3.52 18.60 3.49 18.08 3.11 17.20 3.07 4.7×10-6 
Comparisons of concentration of biochemical biomarkers and plasma fatty acids (log transformed for skewed variable) across quartiles were 
assessed using General Linear Contrast Model adjusted for age, body fat, blood pressure, waist circumference, waist hip ratio, smoking status, 
working energy expenditure and BMI. P-values were corrected by multiple number of traits. 	P-values that exceed 1.0 after correction for 
multiple testing have been marked down to 1.000. QUICKI: quantitative insulin sensitivity check index; PAI-1: plasminogen activator 
inhibitor-1; hs-CRP: high-sensitivity-C-reactive protein; D5D: delta-5-desaturase (20:4n6/20:3n6); D6D: delta-6-desaturase (18:3n6/18:2n6). 
 
 
 
Table 4. Haplotype characteristics of 15-locus, 8-locus and 3-locus haplotypes (n=790). 
Haplotypes Alleles a Number of minor allele Frequency 
15-locus haplotype (rs174537 to rs482548) 
Haplo1 TTGTCTTTCGAATGC 222222221211221 11 17.0% 
Haplo2 GCCCTCCCCCAACCT 111111111111112 1 11.1% 
Haplo3 TTGTCTCTCGTGTCC 222222121222211 11 2.3% 
Haplo4 TTGTCTCTTCTGTCC 222222122122211 11 7.1% 
Haplo5 TTCCTTCTTGAATGC 221112122211221 8 3.0% 
Haplo6 TTGTCTCTTGAATGC 222222122211221 11 1.6% 
Haplo7 GCCCTCCCCCAACCC 11111111111111 0 53.9% 
     
8-locus haplotype (rs174537 to rs99780) 
Haplo1 TTGTCTTT 22222222 8 19.2% 
Haplo2 TTGTCTCT 22222212 7 11.4% 
Haplo3 TTCCTTCT 22111212 4 3.0% 
Haplo4 GCCCTCCC 11111111 0 65.6% 
 
3-locus haplotype (rs2524299 to rs174583) 
Haplo1 TGT 222 3 10.9% 
Haplo2 AAT 112 1 22.8% 
Haplo3 AAC 111 0 65.5% 
a1, major allele; 2, minor allele. 
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Table 5. Estimates of haplotypes effects on plasma linoleic acid, Δ-5 desaturase and Δ-6 desaturase 
(n=790). 
 Plasma LA Δ-5 desaturase Δ-6 desaturase 
Estimates ±SE P value Estimates ±SE P value Estimates ±SE P value 
15-locus haplotype 
Haplo1 0.82±0.24 7.1×10-4 -0.99±0.11 1.81×10-19 -0.004±0.001 4.4×10-9 
Haplo2 0.25±0.28 0.37 -0.10±0.13 0.446 -0.001±0.001 0.211 
Haplo3 1.31±0.53 0.01 -0.86±0.25 6.37×10-4 -0.006±0.001 5.5×10-5 
Haplo4 0.77±0.34 0.02 -0.81±0.15 1.21×10-7 -0.005±0.001 1.1×10-9 
Haplo5 1.74±0.51 6.9×10-4 -0.34±0.23 0.146 -0.006±0.001 4.9×10-6 
Haplo6 0.94±0.70 0.18 -0.87±0.32 6.44×10-3 -0.006±0.002 4.9×10-4 
8-locus haplotype 
Haplo1 0.78±0.22 4.06×10-4 -1.02±1.00 2.45×10-24 -0.003±0.001 8.9×10-10 
Haplo2 0.91±0.27 6.86×10-4 -0.85±0.01 4.27×10-12 -0.005±0.001 6.4×10-15 
Haplo3 1.59±0.50 1.67×10-3 -0.32±0.50 1.67×10-3 -0.006±0.002 8.8×10-6 
3-locus haplotype 
Haplo1 0.86±0.27 1.64×10-3 -0.85±0.13 2.34×10-11 -0.004±0.001 2.4×10-12 
Haplo2 0.90±0.20 1.03×10-5  -0.88±0.09 5.34×10-21 -0.004±0.002 4.7×10-14 
The most common haplotype was used as reference.  
Maximum likelihood estimation adjusted for age, BMI, body fat, waist circumference, working energy expenditure, 
waist hip ratio, blood pressure and smoking habits was used. 
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Table 6. Multiple linear regression analysis of possible plasma linoleic acid determinates with 15-
locus haplotype (n=790). 
 β Coefficient Standard error P Variance explained 
Age (years) -0.047 0.010 <0.001 3.2% 
Waist circumference (cm) -0.036 0.012 0.002 8.1% 
PUFA intakes (%TE) 0.325 0.065 <0.001 3.7% 
Fibre intakes (g/10MJ) 0.035 0.019 0.066 0.5% 
Systolic blood pressure (mmHg) -0.028 0.010 0.002 3.6% 
Body fat (%) -0.040 0.017 0.020 3.7% 
Sugar intakes (%TE) -0.090 0.032 0.005 1.3% 
Carbohydrate intakes (%TE) 0.098 0.027 <0.001 2.0% 
15-locus Haplotype a     3.9% 
Haplo1 0.796 0.253 0.002  
Haplo2 0.455 0.305 0.136  
Haplo3 1.843 0.604 0.002  
Haplo4 1.011 0.345 0.003  
Haplo5 1.177 0.569 0.039  
Haplo6 0.893 0.817 0.275  
a Most common haplotype was used as a reference 
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